CAMBRIDGE, Mass., April 10, 2025 /PRNewswire/ -- Pykus Therapeutics, Inc. ("Pykus" or the "Company") announced today that it has completed enrollment of its pilot study (PYK-2101-RD001) in Australia.

"More than 125,000 people undergo retinal reattachment procedures on a yearly basis in the US. Although our success rate is high, the current recovery process is uncomfortable and inconvenient for ...

-- Results to date demonstrate rapid post-surgical visual recovery with no serious adverse events and meet or exceed FDA target rates for safety and effectiveness – -- Data presented today at ...

(MENAFN- PR Newswire) Please contact the Company directly for more information regarding the Eyecelerator presentation. "PYK-2101 has the potential to offer enormous benefits to patients undergoing ...